2019年ASCO年会：全球基本药物.pptx

Slide1PresentedByNicolaMagriniat2019ASCOAnnualMeeting

Slide2PresentedByNicolaMagriniat2019ASCOAnnualMeeting

ConflictofinterestsPresentedByNicolaMagriniat2019ASCOAnnualMeeting

EssentialMedicinesforcancerbr/ContentsofthepresentationPresentedByNicolaMagriniat2019ASCOAnnualMeeting

EML2017PresentedByNicolaMagriniat2019ASCOAnnualMeeting

AquotationPresentedByNicolaMagriniat2019ASCOAnnualMeeting

EMLsince1977:anearlyevidence-basedadopterPresentedByNicolaMagriniat2019ASCOAnnualMeeting

GlobalaccesstoEssentialMedicinesforcancerbr/ContentsofthepresentationPresentedByNicolaMagriniat2019ASCOAnnualMeeting

Slide9PresentedByNicolaMagriniat2019ASCOAnnualMeeting

MethodologytoupdateEMLin2015PresentedByNicolaMagriniat2019ASCOAnnualMeeting

CancerconsideredinEML2015:22+12PresentedByNicolaMagriniat2019ASCOAnnualMeeting

MeasurementsofBenefit–Example1PresentedByNicolaMagriniat2019ASCOAnnualMeeting

MeasurementsofBenefit–Example2PresentedByNicolaMagriniat2019ASCOAnnualMeeting

NewEMLcancermedicinesmaincriterion:br/magnitudeofabsolutebenefitsPresentedByNicolaMagriniat2019ASCOAnnualMeeting

LanceteditorialOctober24,2015PresentedByNicolaMagriniat2019ASCOAnnualMeeting

EML2017cancerupdatePresentedByNicolaMagriniat2019ASCOAnnualMeeting

EMLcancerdrugs:2015and2017PresentedByNicolaMagriniat2019ASCOAnnualMeeting

Slide18PresentedByNicolaMagriniat2019ASCOAnnualMeeting

2019EMLcancerupdate:br/mainapplicationsPresentedByNicolaMagriniat2019ASCOAnnualMeeting

GlobalaccesstoEssentialMedicinesforcancerbr/ContentsofthepresentationPresentedByNicolaMagriniat2019ASCOAnnualMeeting

Slide21PresentedByNicolaMagriniat2019ASCOAnnualMeeting

Slide22PresentedByNicolaMagriniat2019ASCOAnnualMeeting

CommentstotheproposedcriteriaPresentedByNicolaMagriniat2019